| INTRODUCTION
Hepatitis C virus (HCV) infection is a major public health problem, with an estimated annual incidence of between 3 and 4 million cases and a worldwide prevalence of 2.8%. Between 50% and 80% of infected individuals develop chronic hepatitis C (CHC), which may progress to cirrhosis and hepatocellular carcinoma. 1 Today, because of its extra-hepatic manifestations, CHC is considered a systemic disease. 2 As far as the central nervous system is concerned, around 50% of infected individuals may develop neurological or psychiatric disorders, which are independent of the severity of the liver disease. 3 Among psychiatric and somatic symptoms, up to 80% of patients can suffer from fatigue, 4 and up to 50% present depressive symptoms, anxiety and weakness, 5 causing impairment in social and occupational functioning as well as reduction in quality of life. 6, 7 Moreover, HCV-infected individuals often complain of "brain fog,"
which specifically includes forgetfulness and difficulty concentrating, in addition to fatigue, malaise and anhedonia. 8 In fact, mild cognitive impairment in CHC patients has been reported in many studies, [9] [10] [11] with slower psychomotor speed, alteration in working memory and deficits in attention and concentration being the most commonly observed features. 9, 10 It has been estimated that around one third of infected patients may show neurocognitive disability, even in the absence of cirrhosis and encephalopathy. [12] [13] [14] However, such estimation could had been exaggerated, to the extent that no clear and direct attribution to HCV infection can be made, as other factors may contribute to cognitive impairment in such patients. Several reviews 3, 15, 16 pointed out that confounding factors such as advanced liver disease or history of neuropsychiatric disorder or substance use disorder were not systematically assessed in studies addressing cognitive impairments in CHC patients. Furthermore, most of these studies were cross-sectional, with small samples, and HCV-infected patients were often selected from hospital populations, which may account for selection bias. 16 The high prevalence of neuropsychiatric symptoms reported in CHC is supported by several lines of converging evidence pointing to a neuropathogenic effect of the virus. 13 Several studies suggest that HCV can replicate in monocytes/macrophages, which are able to cross the blood-brain barrier and access to the central nervous system in a process known as "Trojan horse" mechanism. [17] [18] [19] [20] Thus, the brain may serve as an important reservoir for subsequent viral replication, as indicated by the detection of specific HCV-RNA strands in post-mortem brains of CHC patients. 21 Furthermore, the evidence of viral quasi-species diversity between the central nervous system and liver, supports the notion of independent viral evolution, 4 rendering the central nervous system a potential source of relapse after anti-viral therapy. 16 Considering the questionable blood-brain barrier penetration ability of the new direct acting antivirals (DAAs), 22 such reservoir should be taken into account in longterm rebound or outcomes. Late viral relapses are extremely rare after successful treatment with DAAs. 23, 24 However, a recent exhaustive systematic review underlined the absence of evidence to determine the effect of sustained viral response on long-term outcome. 25 Regarding neurobiological consequences, it has been suggested that the infected microglial cells may increase secretion of pro-inflammatory cytokines such as tumour necrosis factor-a (TNF-a) or interleukins (IL), 26 which have been associated with the physiopathology of depressive and cognitive symptoms. 27 Beside some evidence of direct neuroinvasion, the systemic chronic immune system activation that characterises CHC may also account for the pathogenesis of neuropsychiatric symptoms. It is well known that pro-inflammatory cytokines, such as IL-1, IL-6 and TNF-a, may interact with several neurobiological pathways, interfering with neurotransmission and neurotrophic mechanisms. 28 For example, the activation of the indoleamine-2,3-dioxygenase enzyme secondary to neuroinflammation and the consequent induction of the tryptophan catabolites pathways have been related to the depletion of serotonin levels and the augmentation of glutamate neurotoxicity through an increase in quinolinic acid. 29 In the same way, immune activation in central nervous system has been related to a reduced activity of tetra-hydro biopterin, an enzyme involved in dopamine synthesis and whose disruption has been associated with decreased dopamine levels. 30 In the last 2 decades, neuroimaging has been used in HCVinfected patients in the search for in vivo evidence of these central nervous system alterations. 16 Structural and functional techniques have been used to define anatomical alterations, metabolic or neurotransmission abnormalities, and connectivity disruption in CHC. Nevertheless, the majority of these studies centre on demonstrating the neuropsychiatric effects of therapy with interferon-a (IFN-a), which was the main molecule used to treat CHC [31] [32] [33] before the development of the new DAAs, and had been associated with major depressive disorder, malaise and fatigue. 34 Few neuroimaging studies have focused on chronic HCV infection in patients without treatment, and even more less those with a healthy control group. Moreover, the samples selected are heterogeneous, especially with regard to the clinical severity of the CHC, the presence of neuropsychiatric comorbidities and the diagnosis of active substance use disorder. Finally, the attempts to find correlation between neuroimaging findings and cognitive or psychiatric symptoms have yielded inconclusive results. 35 Thus, in order to examine the in vivo evidence of central nervous system alterations in CHC, we performed a systematic review (and meta-analysis if sufficient data were available) of studies investigating HCV chronic-infected patients (treatment naive or previously treated without achieving a sustained viral response), using neuroimaging techniques, and assessed the correlation of these alterations with neuropsychiatric symptoms. 
| METHODS

| Search strategy
A comprehensive, computerised literature search was conducted in MEDLINE, PsycINFO and EMBASE. We searched for the relevant studies published from the earliest available online year until May 2017, using the following key words: "hepatitis C," "chronic hepatitis C," "HCV," "CHC," "structural MRI," "structural magnetic resonance imaging," "functional MRI," "functional magnetic resonance imaging,"
"fMRI," "connectivity," "MRSI," "H-MRS," "spectroscopy," "DTI," "diffusion tensor imaging," "PWI," "perfusion weighted imaging," "PET,"
"positron emission tomography" "SPECT", "single-photon emission computerised tomography," mixed with different Boolean operators "AND" and "OR." Additional studies found in the reference lists of the articles identified were also searched. This search strategy was broadened by tracking the citations of the articles included in Google Scholar. The titles and abstracts were examined, and full-text articles of potentially relevant studies were obtained. After this, inclusion and exclusion criteria were applied, and the articles selected were included in the systematic review (see supporting information for references of excluded articles).
| Study selection
We included only studies published in peer-reviewed journals and written in English, Spanish, Italian and Dutch. To homogenise the selection and to facilitate comparisons, only structural and functional neuroimaging studies with patients with chronic HCV of both genders were included. Additional inclusion criteria were as follows: (1) for cross-sectional designs, studies including treatment naive CHC patients, or patients who had received anti-viral treatment without achieving a sustained viral response, and a healthy control group; (2) for longitudinal design, we selected basal data from studies involving CHC patients treatment naive, or who had received anti-viral treatment without achieving a sustained viral response, with a healthy control group; (3) before the inclusion in the study, patients must have been checked for drug consumption; (4) if a study in the same sample included two or more neuroimaging techniques, these were recorded as separately studies. The exclusion criteria were as fol- 
| Quality assessment
The overall methodological quality of the identified articles was tested with the Newcastle-Ottawa Quality Assessment Scale (NOS), a scale recommended by the Cochrane collaboration for quality assessment of observational studies. 38 For this review, we considered the NOS subscale that evaluates case-control studies which consisted in 9 items grouped in 3 domains of selection, comparability and exposure. Scores may vary from 0 to 9, with higher scores indicated better methodological quality. 3 | RESULTS
| Data synthesis
| Study selection
Of 1403 records, 270 were removed after screened due to duplication, and 1101 were excluded after title/abstract review because they did not meet the selection criteria a priori. Thirty-two full-text articles were then assessed for eligibility. Of these, 14 articles were excluded for various reasons (see Figure 1 and supporting information). Finally, 18 unique references met the inclusion criteria and were included in this systematic review. 11, 35, [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] Figure 1 provides a PRISMA flowchart of study selection for this systematic review. Table S2 in Supporting Information). 
| Characteristics of the included studies
| Magnetic resonance spectroscopy
Twelve case-control studies were identified using proton magnetic resonance spectroscopy (H-MRS). The single voxel spectroscopy method was the most used; in 2 recent studies, 51 ,52 a multivoxel technique was applied. The spectral analysis was mainly conducted with the acquisition mode of the point-resolved spectroscopy (PRESS) technique, which guarantees a better spectral quality. The Stimulated Echo Acquisition Mode (STEAM), which permits a more precise volume selection, was applied in 2 studies. 45, 54 The most frequently studied metabolites were N-acetylaspartate, myoinositol, choline, glutamate
| 1241 plus glutamine and creatine. In Table 1 Table S4 in Supporting Information).
| Choline and choline/creatine ratio
Absolute levels of choline were calculated in 2 studies, 45 and healthy controls. In the study by Bokemeyer et al, 45 significant increases in choline concentration were also reported in parieto-occipital white matter. No differences were found in occipital grey matter, pons, 45 midline grey matter, frontal grey matter or central white matter. 50 In the meta-analysis of 4 studies, choline/creatine levels were increased in centrum semiovale white matter of CHC patients compared with healthy controls (Figure 2 
| Creatine
A meta-analysis of 2 of the studies 45, 50 showed significantly increased creatine levels in the basal ganglia of HCV-infected patients compared with healthy controls ( Figure 2 ). As regards single studies, no significant differences were found in occipital grey matter, parietal-occipital white matter, pons, 45 midline grey matter, frontal grey matter, central white matter 50 and frontal grey matter or white matter, parietal grey matter or white matter. The meta-analysis of 2 of the studies 45, 50 showed increased absolute glutamate plus glutamine levels in basal ganglia of HCV-infected patients compared with healthy controls (Figure 2 ). Significantly increased glutamate plus glutamine levels were also observed in parieto-occipital white matter, 45 but a meta-analysis was not possible because the data available were insufficient. No significant differences were found in occipital grey matter, parieto-occipital white matter, pons, 45 midline grey matter, frontal grey matter, central white matter 50 and frontal grey matter or white matter, parietal grey matter or white matter. 52 Two studies considered the glutamate plus glutamine/ creatine ratio, 47 ,51 but a meta-analysis could not be conducted due to insufficient data. Nevertheless, no significant differences in glutamate plus glutamine/creatine levels were found between CHC patients and healthy controls in centrum semiovale white matter.
| Myoinositol and myoinositol/creatine ratio
Compared with healthy controls, the meta-analysis conducted for 2 of the studies included 45, 50 did not show increased absolute levels of myoinositol in basal ganglia ( Figure S1 in Supporting Information)
in HCV-infected patients. Nevertheless, sensitivity analysis showed significant differences when the fixed effect model was performed, suggesting caution in the interpretation of such results. I 2 was 46%, suggesting moderate heterogeneity (see Figure S1 and Table S4 in supporting information). In the single studies, increased levels of myoinositol were found in bilateral frontal white matter, 52 but no increase in myoinositol was found in occipital grey matter, parietooccipital white matter, pons, 45 midline grey matter, frontal grey matter, central white matter 50 and frontal grey matter, parietal grey matter or white matter. 52 A meta-analysis was also conducted in 3 studies which assessed the myoinositol/creatine ratio in centrum semiovale, 44, 47, 51 but no significant differences were found between CHC subjects and healthy controls. As the previous case, sensitivity
analysis with fixed effect model show significant increased myoinositol/creatine ratio in centrum semiovale of CHC patients. I 2 was 78%, suggesting substantial heterogeneity between studies (see Figure S1 and Three studies 45, 51, 52 provided data on the N-acetylaspartate plus N-acetylaspartate-glutamate peak in patients with CHC, but these data were insufficient for the performance of a meta-analysis. Brain metabolite concentrations were quantitatively analysed by using LCmodel software. 60 Bokemeyer et al 45 reported an increased con- 
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Comparison of metabolite peak levels in basal ganglia and centrum semiovale white matter, between HCV-infected patients and healthy controls. The numbers in parenthesis correspond to the reference. §, § § indicates 2 different imagine techniques in the same study. Cho, choline; Cr, creatine; Glx, glutamine plus glutamate; HCV, hepatitis C virus; MD, mean difference; MRS, magnetic resonance spectroscopy
| Other metabolites
Aspartate, gamma-amino-butyric acid (GABA), glutathione and scylloinositol ratios to creatine levels were analysed in one study. 51 Only glutathione to creatine ratio levels were found increased in the frontal white matter of CHC patients compared with healthy controls. As for the other metabolite levels, no significant differences were found in frontal white matter concentrations.
| Perfusion weighted imaging
Only one study performing perfusion weighted imaging technique in CHC patients was included, 42 which found a reduced regional cerebral blood flow in left temporo-parietal cortex and left frontal cortex in HCV-infected individuals compared with healthy controls. Patients also had an increased regional cerebral blood flow in bilateral basal ganglia compared with healthy controls.
| Positron emission tomography
Three studies used PET imaging technique to study microglial activa- reduced DAT and SERT activity in striatum and hypothalamus/ midbrain in CHC patients compared with healthy controls. This study identified that pathological DAT and SERT binding (with reduction above 2SDs) were present in 60% and 50% of patients, respectively.
The study by Heeren et al 56 reported similar results, observing reduced DAT and SERT activity in CHC patients compared with healthy controls in striatum and hypothalamus/midbrain, respectively. In addition, DAT availability was correlated positively with cerebral metabolic rate of glucose in the superior and inferior parietal and postcentral gyri, the superior medial and inferior frontal gyri, the superior temporal gyrus and the medial cingulated gyrus (all these gyri bilaterally); with the precentral gyrus, the medial temporal gyrus, the temporal pole (on the left); and with insula, putamen, pallidus precuneus and calcarine cortex bilaterally.
| Functional magnetic resonance
One study selected assessed functional connectivity in resting state in CHC patients. 35 Resting-state functional magnetic resonance imaging identified higher eigenvector centrality in patients compared with healthy controls in the right postcentral sulcus and superior parietal lobe. The seed at the significant eigenvector connectivity cluster was used for the analysis. CHC patients presented a higher connectivity between the right postcentral sulcus with primary and secondary somatosensory cortex, paracentral lobule, superior temporal gyrus and occipital lobe compared with healthy controls.
| Diffusion tensor imaging
Diffusion tensor imaging is a neuroimaging technique that provides information on changes at cellular microarchitecture level and is able to detect alterations in normal appearing white matter or grey matter. 61 In our review, we selected 2 studies using diffusion tensor imaging in CHC patients, 43, 52 but no meta-analysis could not be performed because the data were heterogeneous and insufficient. Bladowska et al 43 reported lower fractional anisotropy and increased apparent diffusion coefficient in the inferior fronto-occipital fasciculus in CHC patients than in healthy controls. Thames et al
| Structural magnetic resonance imaging
Two recent studies 35, 49 evaluated the whole brain grey matter volume, finding no differences between HCV patients and healthy controls. Therefore, no meta-analysis was performed. 41 Fatigue and depression scale scores correlations were analysed in the functional connectivity study 35 and in one PET study. 56 Details of correlations between neuroimaging findings and psychometric or neuropsychological evaluations are summarised in Table S3 of Supporting information. 
| DISCUSSION
| Data supporting neuroinflammatory activation in CHC
As mentioned in the introduction, CHC is characterised by a chronic and systemic inflammatory activation, 62 which may lead to inflammation in the central nervous system, interacting with neurons, astrocytes and microglia, even when the immune condition is elicited by innocuous stimuli. 63 A recent study highlighted the role of gut dysbiosis in CHC patients, which is related to endotoxemia and the persistence of systemic inflammation 64 even in patients with sustained viral response. Figure 3 provides an overview of different pathways by which cytokines or active immune cells can cross the blood-brain barrier. 65 Several studies included in our review supported the role of neuroinflammation in CHC patients. Bladowska et al 43 reported
an increased myoinositol/creatine ratio in the posterior cingulate gyrus, an area involved in learning and memory processes which deteriorates in dementia syndromes. 66 An increase in myoinositol levels is associated with glial proliferation, or an increase in glial cell size, which may occur in inflammation. 67, 68 Moreover, the authors 43 observed a positive correlation between myoinositol/creatine levels and grade of portal inflammation, measured by means of the histology activity index score, indicating that inflammatory processes can play a role in the central nervous system involvement. 13 Neuroimmune activation and cytokines may interact with virtually every pathophysiological domain relevant to neuropsychiatric symptoms, including neurotransmitter metabolism, neuroendocrine function, oxidative and nitrosative stress and neural plasticity. 69, 70 This provides an explanation for the metabolic, functional and structural neuroimaging alterations associated with CHC, which have been highlighted in this review. For example, increased levels of the choline/creatine ratio in the centrum semiovale white matter and in basal ganglia of CHC patients, with choline being a marker for cell membrane synthesis and turnover (Table 1) . 71 Augmented choline can be considered a marker of neuroinflammation, reflecting energy failure, membrane degradation or demyelination, 72 and it has been observed in patients with other multi-systemic chronic infections such as HIV patients in the presence of macrophage infiltration. 73 Moreover, blood hypo-perfusion in the frontal and temporo-parietal cortex and hyper-perfusion of basal ganglia of CHC patients was
shown by the means of perfusion weighted imaging, 42 and may be considered a marker of neuroinflammation. 74 Disturbances in cerebral perfusion have been related not only to neuroinflammation but also to the cerebrovascular complications and autoimmune syndromes encountered in HCV-infected patients. 75, 76 Finally, structural neuroimaging studies revealed reduced cortical thickness in the right and left occipital cortex, as well as in the left frontal lobe of patients with CHC, 49 although these results were not replicated in the study by Kharabian Masouleh et al. 35 Neuropsychiatric disorders involving neuroinflammatory response as multiple sclerosis 77 or major depressive disorder 78 have also been related to reduced cortical thickness or global volume.
| Data supporting the role of microglial activation in CHC patients
Several studies in our review have highlighted the role of microglial activation in CHC patients, though results are somewhat controversial. The meta-analysis of 2 PET studies 48, 55 did not show significant differences in glial activation in several brain areas of HCV-infected patients. Nevertheless, important observations are highlighted in the single studies. Grover et al 48 observed increased PK11195 binding potential in caudate nucleus and thalamus of CHC patients versus controls. Up-regulation in binding potential of PK11195 is a selective marker of activated glia, 79 and it has been used as a biomarker of inflammation in Huntington disease or cerebral HIV infection. 80, 81 Interestingly, in the study by Grover et al, 48 HCV viral load was positively correlated with increased PK11195 binding potential, suggesting a possible direct implication of the virus. In line with these observations, we identified significant increased creatine peak levels in basal ganglia of CHC patients compared with healthy controls in the meta-analysis of proton magnetic resonance spectroscopy studies. Creatine is a marker of the energetic system and intracellular metabolism, and it is considered a glial marker since its concentration is much higher in glial cells and grey matter than in neurons and white matter. 71 However, we did not find significant increased levels of the myoinositol absolute peak in basal ganglia, neither increased levels of myoinositol/creatine in centrum semiovale white matter in CHC patients compared with healthy controls, as the meta-analysis was performed, though such results must be interpreted with caution.
Due to its osmolar properties, myoinositol participates in the volume regulation of astrocytes, and high myoinositol levels reflect gliosis, astrocytosis and increased cell membrane turnover (Table 1) . 71, 82 No clear correlations between neuropsychiatric evaluations and neuroimaging findings of glial activation were identified, and the absence of a consistent relationship deserves mention. For example, Grover et al 48 reported significantly increased myoinositol/creatine ratios in basal ganglia of CHC patients, which correlated with increased error rates in a cognitive task involving attention, and similar results were found in patients with major depressive disorder. Indeed, dorsal parietal regions have been related to top-down attentional domain and to episodic memory. 84 Taken together, these data suggest that the reorganisation of the connectivity in the right posterior parietal lobe may be interpreted as a compensatory mechanism that provides more attentional resources.
| Data related to the impact of HCV infection on monoaminergic neurotransmission
Two SPECT studies were included in the review, which illustrated the impact of HCV infection on serotoninergic and dopaminergic neurotransmission. The results showed a reduction in the midbrain serotoninergic and striatal dopaminergic systems in CHC patients (1), as well as pro-inflammatory cytokines and cellular-mediated immune inflammation can communicate with central nervous system crossing the blood-brain barrier through the "neural route" (A), the "humoral route" (B) and the "cellular route" (C). So, both direct virus neuroinvasion and chronic systemic inflammatory activation may contribute to microglia activation and neuroinflammation, which can interact with virtually every pathophysiologic domain relevant to neuropsychiatric symptoms, including neurotransmitter metabolism, oxidative stress and apoptosis. 5HT, serotonin; BBB, blood-brain barrier; BH4, tetra-hydro biopterin; CHC, chronic hepatitis C; CHO, choline; Cr, creatine; DA, dopamine; Glu, glutamate; Glx, glutamate + glutamine; GSH, glutathione; HCV, hepatitis C virus; IDO, indoleamine 2,3 dioxygenase; IL, interleukin; NLRP3, nod-like receptor pyrin-domain containing 3; QUIN, quinolinic acid; TNF-a, tumour necrosis factor-a; TGF-b, transforming growth factor-b; TRYCATs, tryptophan catabolites who exhibit worse cognitive impairment as well as fatigue and depressive symptoms. 53 Actually, alterations in serotonin transmission between raphe nucleus and the prefrontal cortex, amygdala and hippocampus have been associated with mood symptoms and sleep disturbances, 85 whereas dopamine subcortical circuits have been associated with cognitive performance and flexibility, as well as the generation of pleasure. 86, 87 Moreover, data from a randomised clinical trial demonstrated a remission of fatigue symptoms in CHC patients treated with ondaserton, a serotonin receptor 3 antagonist, suggesting an impact of HCV on neurotransmission functions. 88 
| Role of oxidative stress associated with HCV chronic infection
Finally, evidence of oxidative stress derives from the observation of increased glutamate plus glutamine levels in the basal ganglia of HCV-infected patients. Its increase in the basal ganglia is believed to derive from the increase in glutamate. 45, 68 Glutamate is an excitatory neurotransmitter, which can participate in the redox cycle, 82 and its accumulation in the extracellular space may trigger excessive activation of glutamatergic receptors and lead to excitotoxicity. 89 These results are in line with certain reports in major depressive patients, which have found increased glutamatergic transmission that were associated with structural and functional changes in several brain structures as basal ganglia, contributing to oxidative stress. 90 Nevertheless, other study observed lower levels of glutamine plus glutamate in the prefrontal regions, amygdala and hippocampus. 91 The reduction of glutamine plus glutamate levels has been associated with impairments in neuron-astrocyte integrity, as glutamine-glutamate cycle in central nervous system, which may be considered as the neurochemical correlation of neuron-glia interaction. 92 Interestingly, Nagarajan et al 51 found increased levels of glutathione in the basal ganglia of HCV-infected patients, which are indicative of oxidative stress. Oxidative stress plays a central role in neuronal toxicity and loss and has been related to neurodegenerative diseases. 93, 94 Glutathione is crucial for the neutralisation of reactive oxygen species in the central nervous system, 95 and an increase in its levels can be considered as an early marker of inflammation that precedes neuronal damage. Another mechanism involved is microglia activation, which is responsible for the Nod-like receptor pyrin-domain containing 3 (NLRP-3, known as inflammasome) intracellular activity and the consequent production and release of Interleukin-1b. 65 This cytokine has been associated with the mitochondrial dysfunction, apoptosis and reactive oxygen species increase. 27 Moreover, oxidative and nitrosative stress has been related to neurodegenerative diseases, and it is considered a possible pathway of neuroprogression in major depressive disorder. 
